Adding a medicine to the WHO model list of essential medicines
- PMID: 19223877
- PMCID: PMC8052985
- DOI: 10.1038/clpt.2008.258
Adding a medicine to the WHO model list of essential medicines
Abstract
Although the concept of essential medicines is not new, the processes that lead to placement of these medicines on the World Health Organization Model List of Essential Medicines are not well understood. Here, we describe the process by which we added a class of drugs, statins, to the Model List to help combat the growing global epidemic of cardiovascular disease.
Conflict of interest statement
The authors declared no conflict of interest.
Figures
References
-
- Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112:3547–3553. - PubMed
-
- World Health Organization. Shaping the Future. World Health Organization; Geneva: 2003.
-
- Schwartlander B, Grubb I, Perriens J. The 10-year struggle to provide antiretroviral treatment to people with HIV in the developing world. Lancet. 2006;368:541–546. - PubMed
-
- Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol. 2003;32:563–572. - PubMed
-
- Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274:131–136. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
